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Summary The overexpression of the heat-shock proteins hsp9O, hsp70 and hsp27 in human mammary carcinomas has previously been
shown to correlate with reduced overall survival. Moreover, antibodies to hsp9O were detectable in the serum of a large proportion of breast
cancer patients but they were not found in normal controls. High antibody levels also correlated with reduced survival. Here, we show that
antibodies to hsp27 were also detectable in the sera from breast cancer patients but not from normal controls, whereas antibodies to hsp70
were detectable in approximately one-third of both groups. The presence of antibodies to hsp27 was correlated with an improved rather than
a reduced survival, particularly beyond the first 5 years. Hence, the overexpression of hsps in breast cancer cells does not provoke a
generalized immune response to all the hsps. Moreover, the presence of antibodies to different hsps has distinct associations with survival.
These effects are discussed in terms of the mechanisms that provoke an immune response to the hsps and the protective/non-protective
effects of such a response.
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The heat-shock response was first identified in 1962 when Ritossa
described the formation of chromosome puffs in the salivary
glands of the fruit fly Drosophila buksii subjected to temperature
elevation, sodium salicylate or dinitrophenol (Ritossa, 1962).
However, it was not until 1973 that Tissieres demonstrated that
these 'puffing' patterns corresponded with the synthesis ofa group
of proteins, which he named the heat-shock proteins (hsps)
(Tissieres et al, 1974).
The hsps are a group of highly conserved proteins classified
according to their molecular weights, identified originally on the
basis of their increased synthesis after elevated temperature.
Subsequently, these proteins were shown to be synthesized after a
variety of stressful stimuli, such as heavy metals, oxidants, viral
and microbial infections, rendering the cell tolerant to further and
more severe stress. The hsp family has several features in
common: they are preferentially expressed after heat shock; they
are found in both prokaryotic and eukaryotic cells; and with the
exception ofthe small hsps their amino acid sequences are highly
conserved throughout evolution (for reviews see Lindquist, 1986;
Lindquist and Craig, 1988; Creighton, 1990; Latchman, 1991).
The hsps have been classified into families based upon their
molecular weight (MW). In mammals these are hsplOO, hsp9O,
hsp70, hsp60, the 22- to 32-kDa hsps and ubiquitin, which has a
MW of 7-8 kDa. Some members of the hsp70, hsp27 and hsp9O
families have been suggested to play a defined role in human breast
cancer (for review see Conroy and Latchman, 1996). Thus, for
example, overexpression ofhsp27 has been associated with shorter
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disease-free survival in two independent studies (Thor et al, 1991;
Love and King, 1994). Similarly, in patients without nodal involve-
ment, high expression ofhsp70 was associated with shorterdisease-
free survival and, inpatients whohadundergone chemotherapy, was
the only independent predictorofsurvival (Ciocca et al, 1993).
The expression ofhsp90 has been investigated in human breast
cancer and benign tissue (Jameel et al, 1992; 1993). All tissues
were found to have some expression of hsp90, but there were
significantly higher amounts of hsp90 in malignant breast tissue
compared with healthy breast tissue. No significant correlation
was found between hsp90 expression and menopausal status, ER
(oestrogen receptor) status, clinical or histological size or tumour
grade. Medium-term survival (up to 11 years) was increased in
patients with low levels ofhsp90, whereas elevated levels ofhsp90
correlated with poor survival.
Interestingly, overexpression ofhsp9O also occurs in the human
autoimmune disease systemic lupus erythematosus (SLE) (Dhillon
et al, 1993) and in the MRL/lpr mouse autoimmune disease model
(Faulds et al, 1994). In both these cases, the overexpression of
hsp90 is paralleled by the production of autoantibodies to this
protein (Conroy et al, 1994; Faulds et al, 1995).
We have previously studied whether such antibodies to hsp90
could also be observed in breast cancer patients. Indeed, antibodies
to purified hsp90 were detectable in a significant proportion (37%)
of patients with breast cancer but not in normal individuals, or
patients with benign breast tumours and only very rarely in patients
with othertumours (Conroy et al, 1995). The presence ofthese anti-
bodies was found to be correlated with the development of metas-
tases even inpatients withoutaxillary nodal involvement (Conroy et
al, 1995), and in a subsequent study we showed that the presence of
antibodies to hsp90 was associated with decreased survival (Conroy
et al, 1997). Hence the overexpression of hsp90 in breast cancer
patients is indeed associated with the production ofautoantibodies.
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Table 1 Antibodies to hsp27 and hsp7O in sera from breast cancer patients
Samples from breast Samples from
cancer patients healthy control subjects
HSP27
Positive 219 (37.8%) 1 (1.9%)
Negative 360 (62.2%) 52 (98.1%)
Total 579 53
HSP70
Positive 151 (40.9%) 19 (35.9%)
Negative 218 (59.1%) 34 (64.1%)
Total 369 53
In contrast to these studies on hsp90, there have been no
reported studies investigating whether patients with breast cancer
have circulating antibodies to hsp70 and hsp27, and if these anti-
bodies are detected whether they correlate with clinical features or
prognosis of the disease. Such studies are of importance because
overexpression of hsp70 and hsp27, like hsp90, correlates with
poor survival in breast cancer patients and also in order to
determine whether the observed autoimmune response to hsp90 in
breast cancer patients is specific for this hsp or represents a gener-
alized response to all hsps. Thus, for example, in SLE patients we
were unable to detect elevated levels of autoantibodies to hsp70
compared with normal control subjects (Conroy et al, 1994),
although a specific subset of SLE patients shows overexpression
ofhsp70 at the protein level (Dhillon et al, 1993).
Therefore, this study was undertaken to investigate whether
antibodies to hsp70 and hsp27 could be detected in patients with
breast cancer and whetherthe presence ofthe antibodies correlates
with clinical features or prognosis ofthe disease.
PATIENTS, MATERIALS AND METHODS
Patients
Sera were obtained from patients with breast cancer diagnosed at
Guys hospital between 1980 and 1986. Patients presented to the
clinic with unilateral, operable and invasive breast cancer. Patients
tested include both node-negative and node-positive women,
oestrogen receptor-negative and -positive women and pre-, peri-
and post-menopausal women. Samples were taken 1-2 days
before diagnostic excision biopsy and 8-10 days after surgery.
These sera were stored at -20°C until required. Follow-up of
patients was based on 3 monthly visits to the clinic for 3 years then
6 monthly for 2 years and finally annual visits.
There were 579 samples (from 432 women) tested for anti-
bodies to hsp27 (302 before surgery and 277 after surgery). There
were 369 samples (from 289 women) tested for antibodies to
hsp70 (188 before surgery and 181 after surgery). Sera were also
available from 53 healthy female controls.
Methods
ELISA assays were carried out as described previously (Conroy et
al, 1994; Faulds et al, 1995). Nunc Immuno ELISA plates were
coated with hsp27 (0.5 gg ml-' Bioquote, UK) overnight at 4°C
blocked with borine serum albumin (BSA) and goat sera (Sigma
andGibco) at 37°C. Initially, this ELISA was established using D5,
a monoclonal antibody to hsp27 (a gift from Professor R King).
Sera were diluted threefold across the plate starting at a 1:50 dilu-
tion in duplicates. A pool of sera positive for these antibodies was
applied in duplicate at four dilutions on each plate. After washing,
an IgG conjugate (Sigma) was added. The plates were developed
using substrate tablets and read on an ELISA reader at 405 nm.
The ELISA was established after a series of preliminary experi-
ments. The ELISA to hsp70 (bovine hsp70 Sigma) was similar
except that the concentration ofantigen was 2 jig ml-'.
Statistical methods
Survival has been analysed from the date of diagnosis until death
because of breast cancer. All breast cancer patients at Guys are
carefully followed. Women not known to have died were censored
when they were last known to be alive - in most cases at some
stage in 1995 or 1996. Only two patients were censored with less
than 8 years offollow-up. In addition, the survival times ofwomen
dying of causes other than breast cancer were censored at their
time of death. Data were analysed using Cox's proportional
Table 2 Survival of patients with or without antibodies to hsp27, hsp7O or hsp9O in samples taken before or after surgery
Before surgery After surgery
Number of Average Observed Expected Number of Average Observed Expected
samples death rate deaths deaths samples death rate deaths deathsa
per 1000 per 1000
women years of women years of
follow up follow up
Antibodies to hsp27
Negative 176 51 83 74.9 184 47 80 68.4
Positive 126 39 45 53.2 93 28 26 37.6
ND 148 38 P= 0.144 176 49 P= 0.018
Antibodies to hsp7O
Negative 101 53 48 43.9 117 41 46 42.8
Positive 87 42 36 40.1 64 33 22 25.2
ND 265 40 P= 0.368 272 47 P= 0.427
ND, not determined. aAssuming independence of survival with both testing and test result. P-value is based on log-rank test.
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hazards model and other related techniques. To look for differ-
ences in hazard ratios over time, we performed two additional
analyses. In one, all patients still alive at 5 years were censored at
that time. In the other, only those women who lived for at least
5 years were included.
Owing to the large numbers ofwomen forwhom antibody status
was known either before or after surgery (but not both), we also
analysed the data using a stratified Cox model. For each antibody,
the three strata consisted of those women with presurgery results
only, those with post-surgery results only and those with both pre-
and post-surgery results. The average of the two (0-1) test results
was used as the measure ofantibody status in women with two test
results. This model assumes that the presence of hsp antibodies
before surgery has the same effect on survival as the presence after
surgery, but does not assume that the survival rates in the different
strata are the same.
RESULTS
Table 1 summarizes the number of patients and healthy control
subjects with antibodies to hsp27 and hsp7O. There was no signifi-
cant difference in the frequency of antibodies to hsp70 in patients
with breast cancer and healthy control subjects, with these anti-
bodies being detectable in approximately one-third ofboth groups
(no significant difference in a chi-squared analysis). In contrast,
whereas over one-third ofbreast cancer patients had antibodies to
hsp27, these antibodies were only detectable in a single normal
individual (P < 0.001).
To investigate the significance ofthese antibodies, we compared
the survival of women with or without antibodies to hsp27 or
hsp70. The results of this analysis are shown in Table 2, which
includes data from samples taken both shortly before and shortly
after surgery. It is clear from these data that the average rate of
mortality was lower in women with antibodies to hsp27 or hsp70
either before or after surgery than in those who lacked such anti-
bodies. The hazard ratio for hsp27 antibodies in a stratified Cox
regression model was 0.619 (P = 0.006) or0.708 (P = 0.050) when
Kaplan-Meier survival estimate using hsp27
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Figure 1 Survival by antibody results for hsp27. The solid survival curve is
for the 144 patients with at least one positive test and no negative test result.
The broken survival curve is for the 246 women with at least one negative
test result and no positive results. The 42 women with one positive and one
negative result for hsp27 antibodies are not included in the figure
adjusted for age, menstrual status, tumour size, nodal status,
tumour grade and histology. Similarly, the hazard ratio for hsp70
antibodies was 0.790 (P = 0.249) unadjusted or 0.730 (P = 0.134)
when adjusted for the above variables. The hazard ratio for hsp27
was similar in node-negative and node-positive women, oestrogen
receptor-positive or -negative women and in pre-, peri- or post-
menopausal women, although tests for interaction were not signi-
ficant at the 0.05 level. Hence, the presence of hsp27 antibodies
appeared to show a significant association with improved survival,
although the effect for hsp70 was not statistically significant.
These observations contrast with the situation for hsp90 in which
the presence of autoantibodies was associated with relatively
lower survival with the hazard ratio for the unadjusted data being
2.956 (P = 0.135) and 2.298 (P = 0.270) when adjusted for the
above variables (Conroy et al, 1997).
Interestingly, the adjusted hazard ratios associated with hsp27
and hsp70 in the first 5 years (0.94 and 0.80 respectively) were
considerably larger than those for survival beyond 5 years (0.44
and 0.54), but these differences did not reach statistical signifi-
cance. A similar role for antibodies to hsp27 in predicting long-
term survival was also seen when the survival data for patients
with or without hsp27 antibodies are plotted graphically (Figure
1). Thus, the differences in survival between the two groups were
primarily observed after 5 years. Hence, the detection of anti-
bodies to hsp27 around the time of surgery could have greater
prognostic significance for long-term rather than for short-term
survival.
DISCUSSION
The data presented here show that antibodies to hsp27 were
present at enhanced levels in breast cancer patients paralleling the
previously observed overexpression of the protein (Thor et al,
1991; Love and King, 1994). Similar results have also been
obtained previously for hsp90 both at the mRNA (Jameel et al,
1992, 1993) and the antibody (Conroy et al, 1995) levels. In
contrast, despite the similar overexpression ofhsp70 (Ciocca et al,
1993), antibodies to this protein were not detectable at higher
frequency in breast cancer patients vs normal control subjects.
Hence, the immune response observed in breast cancer is not a
generalized response to all the hsps, and in the case of hsp70 it is
apparently possible foroverexpression to occur without provoking
an enhanced immune response. This effect may be associated with
the presence ofantibodies to hsp70 in normal individuals (as well
as in breast cancer patients), whereas antibodies to hsp27 or hsp90
are found only very rarely in normal individuals (this paper and
Conroy et al, 1995).
Onepossibility to account forthepresence ofantibodies tohsp27
and 90 in patients with breast cancer could be that the hsps are
expressed on the cell surface resulting in an immune response.
Thus, hsp70 and hsp90 have been located on cell surfaces of
tumour cells and tumour cell lines (Konno et al, 1989; Ferrarini et
al, 1992; Tsuboi et al, 1994; Multhoffet al, 1995) as well as on the
surface ofperipheral blood cells in SLEpatients (Erkeller-Yuksel et
al, 1993). Similarly, Jameel et al (1992) originally identified the
altered expression ofhsp90 in breast cancer on the basis ofits isola-
tion with an antibody prepared to breast membrane preparations,
again suggesting the appearance ofthis protein on the cell surface.
As there is no structural difference between the hsps in or on
tumour cells and those expressed by normal cells, the question
arises of how these cytosolic proteins become expressed on the
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cell surface ifthey lack sequences for cell-surface translocation. It
is possible that anti-hsp antibodies cross-react with structurally
similar epitopes on unrelated surface molecules, although several
immunoprecipitation experiments suggest that the precipitated
surface molecules are indeed hsps. Alternatively, hsps could be
translocated to the cell surface by unknown mechanisms, possibly
being translocated passively in association with unrelated cell-
surface proteins. The localization of hsp9O and hsp7O to the
surface of tumour cells, in contrast to their normal intracellular
location, suggests a role as markers of tumour cells. Another
possibility is that they are released by adjacent dying cells and
absorbed onto the surface ofintact cells.
Interestingly, in breast cancer patients, antibodies to hsp9O
appear to be associated with the presence of metastases and
reduced survival (Conroy et al, 1995), suggesting that they may
represent an immune response to tumour cells leaving the site of
the original tumour and spreading to other sites. In contrast, anti-
bodies to hsp27 appeared to be associated with enhanced survival,
suggesting that such antibodies may be associated with a protec-
tive effect.
A number of studies have previously investigated the role of
hsps in producing an immune response to tumour cells. Thus, it
has been demonstrated that inbred mice and rats immunized
against their own tumours or tumours of the same genetic back-
ground become immune to challenges with tumour cells
(Srivastava and Old, 1988). This response was tumour specific in
that mice became immune to tumours that were used to immunize
them and not to other tumours.
This led to the concept of immunogenicity, and the search for
cancer-derived molecules that elicited resistance to tumour chal-
lenges. A number of proteins have been identified using this
approach and a large proportion of these were found to be related
to the hsps (see, for example, Ulrich et al, 1986). Given that these
proteins are amongst the most highly conserved proteins between
species throughout evolution, it is unlikely that they are tumour-
specific antigens. Indeed, comparison ofcDNA sequences ofgp96
and hsp9O from healthy tissue and antigenically distinct tumours
did not reveal any differences in DNA sequences (Srivastava et al,
1991). Moreover, hsps isolated from healthy tissues did not elicit
immunity against any tumours tested, i.e. there did not appear to
be any cross-immunity. There was no tumour cross-protection, the
mice could only be immunized against the tumour from which the
peptides were extracted.
Srivastava and Heike (1991) have suggested that hsps may not
be tumour antigens per se but involved in antigen presentation.
Immunization with hsp gp96, hsp9O or hsp7O isolated from
distinct tumours has been shown to result in a specific immune
response against the homologous tumour (Srivastava et al, 1986;
Udono and Srivastava, 1993; Srivastava, 1994). However, it
appears not to be the hsp itself that causes this immune response,
rather the peptides that are attached to it. Hence, in this case, the
protective immune response appears to be directed against some
tumour-specific molecule associated with hsps.
It is possible, however, that such a response might also be
accompanied by an immune response to the associated hsp. In this
model, the antibodies to hsp27 we have detected here would not
themselves be protective but would represent markers of a protec-
tive immune response to tumour-specific components with which
they are associated. However, it is possible that the immune
response to the hsps themselves is directly protective. Thus,
Lukacs et al (1993) showed that tumour cells transfected with the
gene encoding hsp65 in vitro lost tumorigenicity when injected
into animals compared with similar untransfected cells. More
recently, it has been demonstrated that introduction of the hsp65
gene into tumours in vivo also results in the development of an
immune response and rejection ofthe tumour (Lukacs et al, 1997).
Hence, similar effects may also be occurring in the patients with
antibodies to hsp27 resulting in improved survival.
It would be interesting therefore to obtain tumours from patients
with breast cancer and investigate whether the levels of antibody
to hsps are related to levels ofthe particular hsp in the tumour and
also whether hsps can be detected on the cell surface of tumours
in breast cancer patients and whether this relates to clinical
parameters in particular overall survival.
It is already clear, however, that very specific responses to hsps
occur in human breast cancer with antibodies to hsp27 and hsp9O
being detected in a significant number of patients and not of
controls, although this was not the case for hsp7O. Moreover, the
presence of antibodies to hsp27 is associated with improved
survival, whereas the presence of antibodies to hsp9O appeared to
correlate with decreased survival.
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